188 related articles for article (PubMed ID: 25211704)
41. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and in vitro Biological Evaluation of Ferrocenyl Side-Chain-Functionalized Paclitaxel Derivatives.
Plażuk D; Wieczorek A; Ciszewski WM; Kowalczyk K; Błauż A; Pawlędzio S; Makal A; Eurtivong C; Arabshahi HJ; Reynisson J; Hartinger CG; Rychlik B
ChemMedChem; 2017 Nov; 12(22):1882-1892. PubMed ID: 28941201
[TBL] [Abstract][Full Text] [Related]
43. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
44. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.
Blanco-Aparicio C; Carnero A
Biochem Pharmacol; 2013 Mar; 85(5):629-643. PubMed ID: 23041228
[TBL] [Abstract][Full Text] [Related]
45. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Mukhtar E; Adhami VM; Sechi M; Mukhtar H
Cancer Lett; 2015 Oct; 367(2):173-83. PubMed ID: 26235140
[TBL] [Abstract][Full Text] [Related]
46. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
47. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
48. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
[TBL] [Abstract][Full Text] [Related]
49. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
50. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.
Abouzid KAM; Al-Ansary GH; El-Naggar AM
Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341
[TBL] [Abstract][Full Text] [Related]
51. Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.
Zhu L; Zhang C; Lü X; Song C; Wang C; Zhang M; Xie Y; Schaefer HF
J Mol Model; 2020 May; 26(6):162. PubMed ID: 32474655
[TBL] [Abstract][Full Text] [Related]
52. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
53. Design and synthesis of de novo cytotoxic alkaloids by mimicking the bioactive conformation of paclitaxel.
Sun L; Veith JM; Pera P; Bernacki RJ; Ojima I
Bioorg Med Chem; 2010 Oct; 18(19):7101-12. PubMed ID: 20800500
[TBL] [Abstract][Full Text] [Related]
54. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
55. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
56. The Pim kinases: new targets for drug development.
Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
[TBL] [Abstract][Full Text] [Related]
57. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Wang X; Wu E; Wu J; Wang TL; Hsieh HP; Liu X
PLoS One; 2013; 8(6):e65686. PubMed ID: 23762410
[TBL] [Abstract][Full Text] [Related]
58. Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair.
Hsu JL; Leong PK; Ho YF; Hsu LC; Lu PH; Chen CS; Guh JH
Cancer Lett; 2012 Jun; 319(2):214-222. PubMed ID: 22261337
[TBL] [Abstract][Full Text] [Related]
59. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
60. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.
Cicchillitti L; Di Michele M; Urbani A; Ferlini C; Donat MB; Scambia G; Rotilio D
J Proteome Res; 2009 Apr; 8(4):1902-12. PubMed ID: 19714814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
